Literature DB >> 15992972

Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins.

Michiel M Harmsen1, Conny B Van Solt, Helmi P D Fijten, Marga C Van Setten.   

Abstract

The therapeutic parenteral application of llama single-domain antibody fragments (VHHs) is hampered by their small size, resulting in a fast elimination from the body. Here we describe a method to increase the serum half-life of VHHs in pigs by fusion to another VHH binding to porcine immunoglobulin G (pIgG). We isolated 19 pIgG-binding VHHs from an immunized llama using phage display. Six VHHs were genetically fused to model VHH K 609 that binds to Escherichia coli F4 fimbriae. All six yeast-produced genetic fusions of two VHH domains (VHH2s) were functional in ELISA and bound to pIgG with high affinity (1-33 nM). Four pIgG-binding VHH2s were administered to pigs and showed a 100-fold extended in vivo residence times as compared to a control VHH2 that does not bind to pIgG. This could provide the basis for therapeutic application of VHHs in pigs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15992972     DOI: 10.1016/j.vaccine.2005.05.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.

Authors:  Zhiyong Yang; Diane Schmidt; Weilong Liu; Shan Li; Lianfa Shi; Jinliang Sheng; Kevin Chen; Hua Yu; Jacqueline M Tremblay; Xinhua Chen; Kurt H Piepenbrink; Eric J Sundberg; Ciaran P Kelly; Guang Bai; Charles B Shoemaker; Hanping Feng
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

2.  High-level expression of Camelid nanobodies in Nicotiana benthamiana.

Authors:  Yi-Hui Audrey Teh; Tony A Kavanagh
Journal:  Transgenic Res       Date:  2009-10-28       Impact factor: 2.788

3.  Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours.

Authors:  U Iqbal; U Trojahn; H Albaghdadi; J Zhang; M O'Connor-McCourt; D Stanimirovic; B Tomanek; G Sutherland; A Abulrob
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  The molecular mechanism of Shiga toxin Stx2e neutralization by a single-domain antibody targeting the cell receptor-binding domain.

Authors:  Alvin W H Lo; Kristof Moonens; Maia De Kerpel; Lea Brys; Els Pardon; Han Remaut; Henri De Greve
Journal:  J Biol Chem       Date:  2014-07-22       Impact factor: 5.157

Review 5.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

6.  Structure and development of single domain antibodies as modules for therapeutics and diagnostics.

Authors:  Robert J Hoey; Hyeyoung Eom; James R Horn
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

7.  Differential recognition of vascular and parenchymal beta amyloid deposition.

Authors:  Kim S Rutgers; Alexandra van Remoortere; Mark A van Buchem; C Theo Verrips; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch; Sjoerd G van Duinen; Marion L Maat-Schieman; Silvère M van der Maarel
Journal:  Neurobiol Aging       Date:  2009-12-16       Impact factor: 4.673

8.  Isolation of alpaca anti-idiotypic heavy-chain single-domain antibody for the aflatoxin immunoassay.

Authors:  Yanru Wang; Peiwu Li; Zuzana Majkova; Candace R S Bever; Hee Joo Kim; Qi Zhang; Julie E Dechant; Shirley J Gee; Bruce D Hammock
Journal:  Anal Chem       Date:  2013-08-21       Impact factor: 6.986

9.  Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation.

Authors:  M M Harmsen; C B van Solt; H P D Fijten
Journal:  Appl Microbiol Biotechnol       Date:  2009-05-12       Impact factor: 4.813

10.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.